85 results
8-K
EX-99.1
KDNY
Chinook Therapeutics Inc
28 Jul 23
Chinook Therapeutics Announces First Patient Enrolled in Pivotal Phase 3 BEYOND Study of Zigakibart (BION-1301) for Patients with IgA Nephropathy
8:15am
in the BEYOND study, a pivotal phase 3 clinical trial evaluating the safety and efficacy of zigakibart (BION-1301), a potentially disease-modifying anti … , double-blind, placebo-controlled phase 3 clinical trial comparing the safety and efficacy of zigakibart versus placebo in patients with IgAN at risk
DFAN14A
NVS
Novartis AG
10 Jul 23
Additional proxy materials by non-management
4:08pm
and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity
DEFM14A
KDNY
Chinook Therapeutics Inc
10 Jul 23
Proxy related to merger
4:01pm
, the status of our clinical trials and information from our trials that was available to us, including safety data with respect to atrasentan.
On May 15, 2023 … programs and market opportunities, the status of our clinical trials and information from our trials that was available to us, including safety data
PREM14A
KDNY
Chinook Therapeutics Inc
27 Jun 23
Preliminary proxy related to merger
4:02pm
that was available to us, including safety data with respect to atrasentan.
On May 15, 2023, members of our senior management, including Mr. Dobmeier, Eric … and information from our trials that was available to us, including safety data with respect to atrasentan.
On May 16, 2023, Company E provided comments
DEFA14A
4gir67f
20 Jun 23
Additional proxy soliciting materials
9:05am
8-K
EX-99.1
0vi66u
20 Jun 23
CHK-336 was generally well tolerated in healthy volunteers (HV) who received single doses up to 500 mg and multiple doses up to 60 mg for 14 days
9:00am
DEFA14A
949xafnhyqlqzu
12 Jun 23
Additional proxy soliciting materials
4:29pm
8-K
EX-99.1
o06gk rux0
12 Jun 23
Other Events
4:28pm
DFAN14A
px03w
12 Jun 23
Additional proxy materials by non-management
9:41am
DEFA14A
0zorzz0i4 ifz
12 Jun 23
Additional proxy soliciting materials
7:05am
8-K
EX-2.1
vedlba
12 Jun 23
Chinook Therapeutics Enters into Agreement to be Acquired by Novartis AG
7:00am
8-K
EX-99.1
uksl5 po4
9 May 23
Chinook Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Updates
4:03pm
PRE 14A
xdc3wkmmervk6o v3at5
17 Apr 23
Preliminary proxy
4:51pm
8-K
EX-99.2
gtwpl6i4dgog0 76taf
20 May 22
Regulation FD Disclosure
4:11pm
8-K
EX-99.1
h30ohjk wm3k7
20 May 22
Regulation FD Disclosure
4:11pm